BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 29199482)

  • 1. Low dose anti-thymocyte globulin reduces chronic graft-versus-host disease incidence rates after matched unrelated donor transplantation.
    Tandra A; Covut F; Cooper B; Creger R; Brister L; McQuigg B; Caimi P; Malek E; Tomlinson B; Lazarus HM; Otegbeye F; Kolk M; de Lima M; Metheny L
    Leuk Lymphoma; 2018 Jul; 59(7):1644-1651. PubMed ID: 29199482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
    Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Low-dose Anti-thymocyte Globulin as Standard Prophylaxis in Mismatched and Matched Unrelated Hematopoietic Peripheral Stem Cell Transplantation for Hematologic Malignancies.
    Sakellari I; Batsis I; Bousiou Z; Mallouri D; Constantinou V; Gavriilaki E; Smias C; Yannaki E; Kaloyannidis P; Papaioannou G; Stavroyianni N; Syrigou A; Sotiropoulos D; Fylaktou A; Tsompanakou A; Saloum R; Anagnostopoulos A
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):658-666. PubMed ID: 28716402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
    Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Kim CK; Lee KT; Won JH; Hong DS
    Korean J Intern Med; 2016 Jul; 31(4):750-61. PubMed ID: 27017944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor.
    Devillier R; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Harbi S; Granata A; D'Incan E; Coso D; Chabannon C; Picard C; Etienne A; Calmels B; Schiano JM; Lemarie C; Stoppa AM; Bouabdallah R; Vey N; Blaise D
    Am J Hematol; 2014 Jan; 89(1):83-7. PubMed ID: 24108528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
    Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience.
    Butera S; Cerrano M; Brunello L; Dellacasa CM; Faraci DG; Vassallo S; Mordini N; Sorasio R; Zallio F; Busca A; Bruno B; Giaccone L
    Ann Hematol; 2021 Jul; 100(7):1837-1847. PubMed ID: 33948721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superior Graft-versus-Host Disease-Free Relapse-Free Survival in Matched Unrelated Donor Hematopoietic Stem Cell Transplantation with Anti-Thymocyte Globulin (ATG) Compared to Matched Related Donor without ATG.
    Remberger M; Tjønnfjord GE; Abrahamsen IW; Ali M; Myhre AE; Gedde-Dahl T; Fløisand Y
    Transplant Cell Ther; 2021 Jul; 27(7):621.e1-621.e3. PubMed ID: 33895156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
    Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO
    Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of low-dose rabbit anti-thymocyte globulin in unrelated hematopoietic stem cell transplantation.
    Kuriyama K; Fuji S; Inamoto Y; Tajima K; Tanaka T; Inoue Y; Ito R; Hayashi Y; Ito A; Kurosawa S; Kim SW; Yamashita T; Fukuda T
    Int J Hematol; 2016 Apr; 103(4):453-60. PubMed ID: 26857285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
    Finke J; Bethge WA; Schmoor C; Ottinger HD; Stelljes M; Zander AR; Volin L; Ruutu T; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Kolb HJ; Bertz H; Egger M; Grishina O; Socié G;
    Lancet Oncol; 2009 Sep; 10(9):855-64. PubMed ID: 19695955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unrelated Donor Transplant Recipients Given Thymoglobuline Have Superior GRFS When Compared to Matched Related Donor Recipients Undergoing Transplantation without ATG.
    Othman J; Greenwood M; Moore J; Larsen S; Watson AM; Arthur C; Bhattacharyya A; Bilmon I; Blyth E; Bryant A; Bryant C; Dunlop L; Fay K; Gibson J; Hamad N; Kerridge I; Kwan J; Ma D; Micklethwaite K; Milliken S; Panicker S; Stevenson W; Withers B; Wilcox L; Tran S; Gottlieb DJ
    Biol Blood Marrow Transplant; 2020 Oct; 26(10):1868-1875. PubMed ID: 32640314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low rates of acute and chronic GVHD with ATG and PTCy in matched and mismatched unrelated donor peripheral blood stem cell transplants.
    Prem S; Atenafu EG; Al-Shaibani Z; Loach D; Law A; Lam W; Michelis FV; Thyagu S; Kim DDH; Howard Lipton J; Kumar R; Viswabandya A
    Eur J Haematol; 2019 Jun; 102(6):486-493. PubMed ID: 30924973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Thymoglobulin by Stem Cell Source (Peripheral Blood Stem Cell or Bone Marrow) After Myeloablative Stem Cell Transplantation From HLA 10/10-Matched Unrelated Donors: A Report From the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Ravinet A; Cabrespine A; Socié G; Milpied N; Yakoub Agha I; Nguyen S; Michallet M; Menard AL; Maillard N; Mohty M; Suarez F; Huynh A; Marchand T; Deteix C; Cassuto JP; Maury S; Chevallier P; Reman O; Peffault de Latour R; Bay JO
    Transplantation; 2016 Aug; 100(8):1732-9. PubMed ID: 26528768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Rubio MT; Labopin M; Blaise D; Socié G; Contreras RR; Chevallier P; Sanz MA; Vigouroux S; Huynh A; Shimoni A; Bulabois CE; Caminos N; López-Corral L; Nagler A; Mohty M
    Haematologica; 2015 May; 100(5):683-9. PubMed ID: 25769546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-thymocyte globulin for conditioning in matched unrelated donor hematopoietic cell transplantation provides comparable outcomes to matched related donor recipients.
    Portier DA; Sabo RT; Roberts CH; Fletcher DS; Meier J; Clark WB; Neale MC; Manjili MH; McCarty JM; Chung HM; Toor AA
    Bone Marrow Transplant; 2012 Dec; 47(12):1513-9. PubMed ID: 22580767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis.
    Russell JA; Turner AR; Larratt L; Chaudhry A; Morris D; Brown C; Quinlan D; Stewart D
    Biol Blood Marrow Transplant; 2007 Mar; 13(3):299-306. PubMed ID: 17317583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.